BR112017005666A2 - micropartículas injetáveis para liberação hiper-localizada de agentes terapêuticos - Google Patents

micropartículas injetáveis para liberação hiper-localizada de agentes terapêuticos

Info

Publication number
BR112017005666A2
BR112017005666A2 BR112017005666A BR112017005666A BR112017005666A2 BR 112017005666 A2 BR112017005666 A2 BR 112017005666A2 BR 112017005666 A BR112017005666 A BR 112017005666A BR 112017005666 A BR112017005666 A BR 112017005666A BR 112017005666 A2 BR112017005666 A2 BR 112017005666A2
Authority
BR
Brazil
Prior art keywords
hyper
therapeutic agents
injectable microparticles
localized release
microparticles
Prior art date
Application number
BR112017005666A
Other languages
English (en)
Inventor
M Malone Amanda
A Helliwell James
Original Assignee
Eupraxia Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eupraxia Pharmaceuticals Inc filed Critical Eupraxia Pharmaceuticals Inc
Publication of BR112017005666A2 publication Critical patent/BR112017005666A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

resumo ?micropartículas injetáveis para liberação hiper-localizada de agentes terapêuticos? micropartículas injetáveis carregadas com fármaco, composição farmacêutica das mesmas e métodos para usar as mesmas em um compartimento do corpo ou para administração sistêmica são descritos neste relatório.
BR112017005666A 2014-09-19 2015-09-18 micropartículas injetáveis para liberação hiper-localizada de agentes terapêuticos BR112017005666A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462052959P 2014-09-19 2014-09-19
PCT/US2015/051072 WO2016044799A1 (en) 2014-09-19 2015-09-18 Injectable microparticles for hyper-localized release of therapeutic agents

Publications (1)

Publication Number Publication Date
BR112017005666A2 true BR112017005666A2 (pt) 2017-12-19

Family

ID=55533935

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017005666A BR112017005666A2 (pt) 2014-09-19 2015-09-18 micropartículas injetáveis para liberação hiper-localizada de agentes terapêuticos

Country Status (14)

Country Link
US (1) US20170246117A1 (pt)
EP (1) EP3193847A4 (pt)
JP (1) JP2017528527A (pt)
KR (1) KR20170056573A (pt)
CN (1) CN107106506A (pt)
AU (1) AU2015317339A1 (pt)
BR (1) BR112017005666A2 (pt)
CA (1) CA2960860A1 (pt)
CL (1) CL2017000664A1 (pt)
IL (1) IL251216A0 (pt)
MX (1) MX2017003638A (pt)
RU (1) RU2017113354A (pt)
SG (2) SG11201701870PA (pt)
WO (1) WO2016044799A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101951075B1 (ko) 2013-03-21 2019-02-21 유프락시아 파마수티컬스 유에스에이 엘엘씨 주입가능한 서방성 방출 조성물 및 관절 내 염증 및 이와 관련된 통증을 치료하기 위해 이를 사용하는 방법
GB201505527D0 (en) 2015-03-31 2015-05-13 Jmedtech Pte Ltd Composition
EP3206672B1 (en) 2015-10-27 2018-03-14 Eupraxia Pharmaceuticals Inc. Sustained release formulations of local anesthetics
AU2018345844B2 (en) 2017-10-06 2024-03-07 Foundry Therapeutics, Inc. Implantable depots for the controlled release of therapeutic agents
SG11202005949UA (en) 2018-05-24 2020-07-29 Celanese Eva Performance Polymers Corp Implantable device for sustained release of a macromolecular drug compound
CN111971026A (zh) 2018-05-24 2020-11-20 塞拉尼斯伊娃高性能聚合物公司 用于持续释放大分子药物化合物的可植入器件

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4568559A (en) * 1984-02-06 1986-02-04 Biotek, Inc. Composite core coated microparticles and process of preparing same
US5922340A (en) * 1992-09-10 1999-07-13 Children's Medical Center Corporation High load formulations and methods for providing prolonged local anesthesia
GB0027357D0 (en) * 2000-11-09 2000-12-27 Bradford Particle Design Plc Particle formation methods and their products
EP1363602A4 (en) * 2001-01-25 2006-01-11 Euro Celtique Sa LOCAL ANESTHESIA, AND METHOD OF USE
CA2510320C (en) * 2002-12-20 2012-10-09 St. James Associates Llc/Faber Research Series Coated particles for sustained-release pharmaceutical administration
US20040191326A1 (en) * 2003-03-31 2004-09-30 Reo Joseph P. Taste-masking vehicle for coated oxazolidinone particles
US8110284B2 (en) * 2003-07-31 2012-02-07 Sol-Gel Technologies Ltd. Microcapsules loaded with active ingredients and a method for their preparation
JP5345141B2 (ja) * 2007-06-25 2013-11-20 大塚製薬株式会社 コア／シェル構造を有するマイクロスフェア
US8846068B2 (en) * 2008-04-18 2014-09-30 Warsaw Orthopedic, Inc. Methods and compositions for treating post-operative pain comprising a local anesthetic
CN102070895B (zh) * 2010-11-17 2013-03-27 无锡中科光远生物材料有限公司 一种核壳结构微胶囊及其制备方法
JP6083936B2 (ja) * 2011-03-11 2017-02-22 大阪ガスケミカル株式会社 徐放性粒子の製造方法
CA2853965A1 (en) * 2011-11-03 2013-05-10 Gtx, Inc. Pharmaceutical compositions of selective androgen receptor modulators and methods of use thereof
US20150044271A1 (en) * 2012-02-27 2015-02-12 O-Ray Pharma, Inc. Solid drug implants for intracochlear delivery of therapeutics for the treatment of otic disorders
KR101951075B1 (ko) * 2013-03-21 2019-02-21 유프락시아 파마수티컬스 유에스에이 엘엘씨 주입가능한 서방성 방출 조성물 및 관절 내 염증 및 이와 관련된 통증을 치료하기 위해 이를 사용하는 방법

Also Published As

Publication number Publication date
SG10201902407PA (en) 2019-04-29
RU2017113354A (ru) 2018-10-19
CL2017000664A1 (es) 2018-03-02
RU2017113354A3 (pt) 2019-04-18
EP3193847A1 (en) 2017-07-26
WO2016044799A1 (en) 2016-03-24
EP3193847A4 (en) 2018-06-06
CA2960860A1 (en) 2016-03-24
MX2017003638A (es) 2017-11-08
IL251216A0 (en) 2017-05-29
KR20170056573A (ko) 2017-05-23
SG11201701870PA (en) 2017-04-27
US20170246117A1 (en) 2017-08-31
AU2015317339A1 (en) 2017-04-27
CN107106506A (zh) 2017-08-29
JP2017528527A (ja) 2017-09-28

Similar Documents

Publication Publication Date Title
BR112017005666A2 (pt) micropartículas injetáveis para liberação hiper-localizada de agentes terapêuticos
PH12018500586A1 (en) Farnesoid x receptor agonists and uses thereof
HK1248548A1 (zh) 用於將治療劑和診斷劑遞送到細胞中的方法、組合物和系統
SV2017005355A (es) Composiciones de portador-anticuerpo y métodos para realizarlas y utilizarlas
MX2018008190A (es) Sistemas y metodos para la administracion transdermica a largo plazo.
CL2016002269A1 (es) Moduladores alostéricos del núcleo proteico de la hepatitis b.
CL2016002072A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
BR112015022625A2 (pt) micromatrizes para entrega de agente terapêutico e métodos de uso
MY187540A (en) Compounds active towards bromodomains
BR112017000528A2 (pt) moduladores dos receptores toll-like para o tratamento do hiv
ES2969758T3 (es) Composiciones farmacéuticas para usar en la terapia de la blefaritis
BR112015024234A2 (pt) composição de liberação sustentada injetável e método para o uso da mesma para tratar inflamação em articulações e dor associada com a mesma
CL2018000565A1 (es) Compuestos derivados de piridinona dicarboxamida, inhibidores de bromodominio; composicion farmaceutica; combinacion farmaceutica; utiles en el tratamiento de enfermedades autoinmunitarias, inflamatorias, virales y cancer, entre otras.
CL2018001108A1 (es) Composiciones y métodos para transducción de tumores
MX2023006706A (es) Administracion transdermica de agentes grandes en composiciones de emulsion mediante acondicionamiento de la piel con microagujas y sus usos.
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
EA201991447A1 (ru) Снижение вязкости фармацевтических составов
MX2015010791A (es) Metodos para tratar el cancer y prevenir la resistencia a farmacos.
CY1122403T1 (el) Μορφες δοσολογιας και θεραπευτικες χρησεις της l-4-χλωροκυνουρενινης
EA201992612A1 (ru) Схемы применения антагониста гонадотропин-высвобождающего гормона для лечения эндометриоза
BR112018071370A2 (pt) composições farmacêuticas orais de mesalazina
BR112018070497A2 (pt) métodos e formulações farmacêuticas para tratamento de condições oculares
EA201890457A1 (ru) Комбинации антитела против ox40 и модулятора tlr4 и их применение
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
PH12016502243A1 (en) Pharmaceutical compositions for treating infectious diseases

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements